ULB, CHU Saint-Pierre, Hôpital Erasme, ULiège - FNRS

" The project investigates the immune responses to SARS-CoV-2 infection in humans. Cohorts of patients and contacts are recruited and followed-up during several months following infection. Using systems serology and systems biology approaches, the quality and dynamics of antibody and cellular responses are analysed to identify correlates of protection against severe disease and to determine the duration of natural immunity to the virus. The project should provide insight in the host response to SARS-CoV-2 and should help define deconfinement strategies and develop prophylactic and therapeutic interventions against COVID-19. "
Funding: COVID 19 - ULB
Contact: Arnaud Marchant: This email address is being protected from spambots. You need JavaScript enabled to view it. Stanislas Goriely: This email address is being protected from spambots. You need JavaScript enabled to view it.

ZENTECH SA
" Development of specific IVD products to detect the patient serology due to the infection with SARS-COV2 Developement based on ISO13485, Directives 98/79/EC standards. Different technologies approched : ELISA, RT-PCR, lateral flow "
Contact: Alain Bosseloir COO ZenTech sa Liege Science Park Avenue du Pré Aily 10 4031 Angleur

Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...

Read more: Alexandre Di Paolo, Business Development Manager

ULiège - Royal Academy of Sciences, Letters and Fine Arts of Belgium
"The Centre for Protein Engineering (CIP, ULiège), through its two technological platforms, has been involved in the production of reagents (i.e. proteins) for diagnostic and analyses of SARSCoV-2 infection. In particular, Protein Factory has produced a pure and highly active enzyme (CAS12) for a CRISPR/CAS assay, which, in combination with classical PCR technology allows rapid detection of the virus. Automated screening is currently performed at Robotein for optimal formulation of CAS12. The production of complementary protein reagents for such tests is underway. Furthermore, in a collaborative effort with Dr Arnaud Marchant at Institut d'Immunologie Médicale (ULB), the CIP is involved in the design and production of recombinant SARS-COV-2 antigens towards the development of a platform for high dimensional systems serology analysis of SARS-CoV-2 antibodies."
Contact: André Matagne This email address is being protected from spambots. You need JavaScript enabled to view it. 

Institut Jules Bordet
" Contribution to the application and implementation of a novel Covid-19 diagnostic testing method developed at the GIGA/FARAH academic research institutes. Starting with a handful academic scientists from different disciplines, we established a Covid diagnostic lab with the goal of increasing the testing capacity in Belgium during the heaviest period of the crisis. The lab was entirely and exclusively build by training academic volunteers dedicating their time and energy to a joint effort to "beat the virus". Today the lab has a testing capacity of > 3000 samples/day, 7days/7. The diagnostic lab contributed - and still contributes - to the federal Testing Task Force as one of the five partners involved in screening nursing homes and more recently "centres de triage". We believe extensive testing may be critical to assist and better understand the nascent "deconfinement". Making available our expertise in virus-associated diseases accumulated over years of...

Read more: Anne Van den Broeke, Doctor

UNamur - Royal Academy of Medicine of Belgium - Royal Academy of Sciences, Letters and Fine Arts of Belgium
" UNamur researchers have developed a procedure for the detection of SARS-CoV-2. The protocol has been approved by the Federal Agency for Medicines and Health Products (FAMHP). As successfully realized within UNamur, the method can be implemented in a molecular biology research lab to be used for diagnostic purposes on clinical samples. It requires little technological development and allows to overcome reagents shortage or availability of automated systems. To support the implementation of the diagnostic procedure, the required equipment and logistical means have been described in a "starting pack" document accompanying the protocol. "
Publication References: The protocol and starting pack can be downloaded here: https://www.narilis.be/news/sana-sars-cov-2-namur
Contact: Virginie Bourguignon This email address is being protected from spambots. You need JavaScript enabled to view it.

UCLouvain
" Production of SARS-Cov-2 glycoproteins in glyco-engineered plant suspension cells to obtain homogenous and predefined N-glycosylation profiles, characterize their binding and/or produce vaccine. "
Funding: Own funding and WALInnov
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. UCLouvain/LIBST

ULB, Department of Pathology, Erasme hospital and DIAPath-CMMI - Royal Academy of Medicine of Belgium
" A first objective of this project is to establish an accurate topography of the SARS-CoV-2 virus in the organs and various cells of patients who died in COVID-19 units, in order to contribute to a better understanding of the pathogenesis of COVID-19. A second objective is to provide a routine diagnostic test for the detection of SARS-CoV-2 in routine samples in pathological anatomy. "
Funding: Fonds Y Boël (Brussels, Belgium), Fonds Erasme pour la Recherche Médicale (Brussels, Belgium), and "Appel à projet Spécial COVID-19 - ULB" (Brussels, Belgium). The CMMI is supported by the European Regional Development Fund and the Walloon Region of Belgium (Wallonia-biomed; grant no. 411132-957270; project "CMMI-ULB").
Contact: Prof. I. Salmon, Department of Pathology, Erasme Hospital, Université Libre de Bruxelles (ULB), Route de Lennik 808, 1070 Brussels, Belgium.

Covartim
"In the global effort to help the healthcare professionals in the fight against the Covid pandemic, we are providing documents to help manufacturers that are not familiar with medical devices to properly document their work to help them in their product development and achieving compliance. These templates are derived from our technical file documentation and include some reference to guidances (mostly applicable in Belgium) for devices and accessories to answer to hospital products shortage."
Contact : Covartim www.covartim.be This email address is being protected from spambots. You need JavaScript enabled to view it.

ULB
" We are developing a prototype, upon the request of Médecins Sans Frontières | MSF Belgique, with aim to monitor key parameters of a patient's health - levels of oxygen saturation in the blood, heart rate and temperature - in order to detect a potential covid19 infection, and to adapt the patient care accordingly. The prototype is wearable, battery powered, and send its data wirelessly. In this regard, the patient can be remotely monitored. "
Funding: Own funds
Publication References: None.
Contact: Primary contact: Antoine Nonclercq - This email address is being protected from spambots. You need JavaScript enabled to view it. ULB BEAMS (Oriane Bastin - This email address is being protected from spambots. You need JavaScript enabled to view it. & Ken Hasselmann - This email address is being protected from spambots. You need JavaScript enabled to view it. & Antoine Nonclercq - This email address is being protected from spambots. You need JavaScript enabled to view it. & Michel Osée - This email address is being protected from spambots. You need JavaScript enabled to view it. & François Quitin - This email address is being protected from spambots. You need JavaScript enabled to view it.) ULB LISA (Olivier Debeir - This email address is being protected from spambots. You need JavaScript enabled to view it. & Rudy Ercek - This email address is being protected from spambots. You need JavaScript enabled to view it.) ULB Smart Campus (Jean Landercy - This email address is being protected from spambots. You need JavaScript enabled to view it.)

ULiège, CHU - Royal Academy of Medicine of Belgium
" Nous faisons face à une pandémie d'infection COVID-19. Ce virus pathogène est source de complications pulmonaires aggravant fortement le pronostic de nos patients. De nos jours, tant les mécanismes physiopathologiques en cause que les marqueurs de sévérité de l'atteinte restent indéterminés. Il apparaît donc comme urgent de pouvoir identifier des marqueurs diagnostiques, pronostiques et prédictifs pour nos patients. Dans ce contexte, plusieurs voies rapidement explorables nous apparaissent comme critiques. Le but final de cette étude est de contribuer à une prise en charge plus ciblée des patients porteurs d'une infection au SRAS-Cov-2. "
Funding: Fonds Léon Frederic
Publication References: Dix publications représentatives : 1) Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. HUMBLET C, GREIMERS R, DELVENNE P, DEMAN J, BONIVER J, DEFRESNE MP. J Natl Cancer Inst 88 (1996), 824-831. IF...

Read more: Ph. DELVENNE, FNRS Research Director / Chef de service Anatomie pathologique - J. GUIOT, Chef de...

Any-Shape
" Production of nasopharyngeal swabs using 3D printing "
Contact: Roger Cocle CEO This email address is being protected from spambots. You need JavaScript enabled to view it.

GIGA-Institute, ULiège - FNRS - Royal Academy of Sciences, Letters and Fine Arts of Belgium
" The main objective of our research program is the identification of human genetic factors impacting the COVID19 pandemic. Within the COVID-19 host genetics initiative (https://www.covid19hg.org/), we will establish a shared set of phenotypes to be combined with genomic data for standard GWAS and further meta-analysis. Field of expertise of our laboratory : genetics, genomics, bioinformatics, immune-response related diseases. In addition, the GIGA Institute is an interdisciplinary research institute from the ULiege devoted to academic excellence in the biomedical sciences to foster ground-breaking medical innovation. It comprises 583 members attached to six faculties (Medicine, Science, Veterinary Medicine, Engineering, Agbiotech, Psychology) that are organized in four disease-based (neuroscience, cancer, infection-inflammation-immunity, cardiovascular) and two method-based thematic units...

Read more: Souad Rahmouni, Doctor

UMONS and Ambroise-Paré Hospital Mons
" Predictive plasma signature of the clinical behavior of COVID-19 patients. The clinical presentation of COVID-19 infection varies from mild to asymptomatic to pneumonia, which can be complicated by severe respiratory failure and/or cardiovascular, renal, hepatic and cutaneous involvement. The understanding of such a polymorphism is very incomplete and the prognosis is difficult. Several tracks involving inflammatory reactions are currently favored to better explain this disease. In particular, the significant increase in plasma cytokines IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A and TNFα, known as "cytokine storm", seems to be significantly associated with the ARDS and multi-organ onsets. In this context, IL6 seems to play an important role and targeted treatments against this cytokine seem promising. Also, the infection of endothelial cells by the coronavirus causing endothelium inflammation have been suggested as one of the fundamental...

Read more: Stéphane CARLIER, Prof - Jean-Marie COLET, Prof - Fabrice JOURNE, Dr - Sven SAUSSEZ, Prof- Vincent...

Materia Nova
" Based on its expertise on surface treatments and biotechnology, Materia Nova is actively working on the development of decontamination process or anti-viral surface treatments. On the one one hand, plasma technology can be used to decontaminate surfaces or fabric, like sanitary masks. Beyond masks, this technique can be used for the sterilization of medical parts (respirator tubing, surgical instruments...) even sensitive to temperature. The technology can be declined in the form of a small system that could also be useful in structures other than hospitals such as nursing homes, shops... On the other hand, the knowledge of Materia Nova in wet and dry functional coatings dedicated to various properties and applications (transport, health, energy,…) helps to investigate the anti-viral surface treatment. Due to this large panel of technologies (plasma deposition, sol-gel, organic coating or electrodeposition), the coatings or the combination of coatings can be applied on...

Read more: Stéphanie Roosa, Program Leader Biotechnology - Thomas Godfroid, Scientific Leader Plasma...